Education
About Us
Working with TipRanks
Follow Us
Tandem Diabetes Care (TNDM)
NASDAQ:TNDM
TNDM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$9.98 - $47.60
Previous CloseN/A
Volume336.73K
Average Volume (3M)2.14M
Market Cap
$758.81M
Enterprise Value$1.38B
Total Cash (Recent Filing)$368.63M
Total Debt (Recent Filing)$493.20M
Price to Earnings (P/E)―
Beta1.09
Next Earnings
Oct 29, 2025EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.48
Shares Outstanding67,569,470
10 Day Avg. Volume2,877,033
30 Day Avg. Volume2,136,887
Financial Highlights & Ratios
PEG Ratio0.43
Price to Book (P/B)8.96
Price to Sales (P/S)2.51
P/FCF Ratio472.08
Enterprise Value/Market Cap1.82
Enterprise Value/Revenue1.26
Enterprise Value/Gross Profit2.70
Enterprise Value/Ebitda-9.18
Forecast
1Y Price Target
$20.42Price Target Upside81.83% Upside
Rating ConsensusHold
Number of Analyst Covering21
Bulls Say, Bears Say
Bulls Say
Market ExpansionNumerous commercial catalysts, including the Type 2 label, SteadiSet extended wear tubing, and Tobi, provide potential for future growth.
Product InnovationTNDM showcased advancements in its product pipeline, particularly the Mobi tubeless, which is in final packaging form and undergoing validation testing.
Revenue GrowthWorldwide revenue was $240.7M, up 9% year over year, which exceeded the Street’s $238.6M estimate.
Bears Say
Domestic Business OutlookThe outlook for the domestic business is weaker-than-expected, with renewals in the U.S. expected to be flat next year.
Sales GuidanceTNDM reduced its 2025 US sales guidance to $700M from $725M-$730M, citing its commercial transformation as well as increased US competition.
US Market ChallengesThe uptake of Mobi simply is not as strong as expected and TNDM is likely a third choice among the T2 population.
Tandem Diabetes Care News
TNDM FAQ
What was Tandem Diabetes Care’s price range in the past 12 months?
Tandem Diabetes Care lowest stock price was $9.98 and its highest was $47.60 in the past 12 months.
What is Tandem Diabetes Care’s market cap?
Tandem Diabetes Care’s market cap is $758.81M.
When is Tandem Diabetes Care’s upcoming earnings report date?
Tandem Diabetes Care’s upcoming earnings report date is Oct 29, 2025 which is in 78 days.
How were Tandem Diabetes Care’s earnings last quarter?
Tandem Diabetes Care released its earnings results on Aug 06, 2025. The company reported -$0.482 earnings per share for the quarter, missing the consensus estimate of -$0.399 by -$0.083.
Is Tandem Diabetes Care overvalued?
According to Wall Street analysts Tandem Diabetes Care’s price is currently Undervalued.
Does Tandem Diabetes Care pay dividends?
Tandem Diabetes Care does not currently pay dividends.
What is Tandem Diabetes Care’s EPS estimate?
Tandem Diabetes Care’s EPS estimate is -0.32.
How many shares outstanding does Tandem Diabetes Care have?
Tandem Diabetes Care has 67,569,470 shares outstanding.
What happened to Tandem Diabetes Care’s price movement after its last earnings report?
Tandem Diabetes Care reported an EPS of -$0.482 in its last earnings report, missing expectations of -$0.399. Following the earnings report the stock price went down -19.944%.
Which hedge fund is a major shareholder of Tandem Diabetes Care?
Currently, no hedge funds are holding shares in TNDM
Tandem Diabetes Care Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$20.42 (81.83% Upside)
$20.42 (81.83% Upside)
Blogger Sentiment
Neutral
TNDM Sentiment 50%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 801.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $251.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 1.1%
Last 30 Days ▲ 1.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-69.54%
12-Months-Change
Fundamentals
Return on Equity
-111.91%
Trailing 12-Months
Asset Growth
-6.59%
Trailing 12-Months
Company Description
Tandem Diabetes Care
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set. It also provides t:slim X2 insulin with Basal-IQ and control IQ technology; t:slim X2 with G5 Integration; and Tandem Device Updater, a tool that allows users to update their pump's software. In addition, the company offers t:connect, a web-based data management application, which provides a visual way to display diabetes therapy management data from the pump, continuous glucose monitoring, and supported blood glucose meters for users, their caregivers, and their healthcare providers; and Sugarmate, a mobile app for people with diabetes who use insulin. It has development and commercialization agreements with Dexcom, Inc. and Abbott Laboratories. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.
TNDM Company Deck
TNDM Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong international sales growth, significant progress in pharmacy channel expansion, and product development milestones. However, it also pointed out challenges in the U.S. market with moderated sales growth and increased competition. Despite these challenges, the company remains optimistic about its long-term goals.View all TNDM earnings summariesTNDM Revenue Breakdown
74.21% U.S.
25.79% International
TNDM Stock 12 Month Forecast
Average Price Target
$20.42
▲(81.83% Upside)
Technical Analysis
Ownership Overview
0.92% Insiders
28.56% Mutual Funds
0.22% Other Institutional Investors
45.33% Public Companies and
Individual Investors